Drug Trial Radar · NCT02426684
Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
Last checked: Nov 19, 2026Latest source record: May 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Jun 16, 2015
Primary completion
Nov 10, 2017
Study completion Nov 10, 2017
Sponsor
- Lead sponsor
- Cedars-Sinai Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hansa Biopharma AB
- First posted
- Apr 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single center phase I/II open label, exploratory study assessing safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney transplantation. We hope that IdeS® will help eliminate DSAs in HS patients who are DSA+ and flow cytometry (FCMX) crossmatch + at time of transplant. We plan to enroll a total of 20 patients. Patients will be followed for 6 months post administration of IdeS®.
Conditions
- Renal Disease
Interventions
IdeS® (Imlifidase)Drug
0.24mg/kg IdeS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Allograft RejectionTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.